NASDAQ: LQDALiquidia Corp Stock
$13.72+0.04 (+0.29%)
Updated Apr 17, 2025
LQDA Price
$13.72
Fair Value Price
N/A
Market Cap
$1.17B
52 Week Low
$8.26
52 Week High
$16.81
P/E
-8.27x
P/B
15.14x
P/S
66.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.00M
Earnings
-$130.39M
Gross Margin
58%
Operating Margin
-842.44%
Profit Margin
-931.7%
Debt to Equity
1.98
Operating Cash Flow
-$93M
Beta
0.97
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LQDA Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LQDA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LQDA
Ranked#267 of 463
Ranked#267 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important LQDA news, forecast changes, insider trades & much more!
LQDA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LQDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LQDA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LQDA is poor value based on its book value relative to its share price (15.14x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
LQDA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LQDA due diligence checks available for Premium users.
Valuation
LQDA fair value
Fair Value of LQDA stock based on Discounted Cash Flow (DCF)
Price
$13.72
Fair Value
-$12.79
Undervalued by
207.26%
LQDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LQDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.27x
Industry
-177.72x
Market
27.98x
LQDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.14x
Industry
4.05x
LQDA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LQDA's financial health
Profit margin
Revenue
$2.9M
Net Income
-$38.4M
Profit Margin
-1,315.4%
LQDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LQDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$230.3M
Liabilities
$153.0M
Debt to equity
1.98
LQDA's short-term assets ($185.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LQDA's short-term assets ($185.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LQDA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LQDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.8M
Investing
-$4.8M
Financing
-$2.3M
LQDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LQDA vs Biotech Stocks
Liquidia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.